Alaunos Therapeutics (TCRT) EBITDA (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly EBITDA came in at -$1.0 million in Q1 2026, up 7.33% YoY from -$942921.5 in Q1 2025, and down 11.58% on a QoQ basis from -$907000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) EBITDA (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of EBITDA data on file, last reported at -$1.0 million in Q1 2026.
- Quarterly EBITDA rose 7.33% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (changed 0.43% YoY) and the FY2025 annual result came in at -$4.2 million, up 12.2% from the prior year.
- EBITDA eased to -$1.0 million in Q1 2026, from -$907000.0 in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$755000.0 in Q4 2024 to a low of -$9.7 million in Q1 2023.
- A 5-year average of -$4.7 million and a median of -$1.7 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA soared 90.5% — and 2025, when it slipped 20.13%.
- Tracing TCRT's EBITDA over 5 years: stood at -$8.5 million in 2022, then climbed by 6.71% to -$7.9 million in 2023, then soared by 90.5% to -$755000.0 in 2024, then fell by 20.13% to -$907000.0 in 2025, then fell by 11.58% to -$1.0 million in 2026.
- The last three EBITDA figures came in at -$1.0 million (Q1 2026), -$907000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 133.12 Mn |
| 10 | Alaunos Therapeutics | 4.26 Mn | 4.13 Mn | - | -952,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.01 Mn |
| Dec 31, 2025 | -907,000.00 |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -1.04 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | -755,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -7.95 Mn |
| Sep 30, 2023 | -8.66 Mn |
| Jun 30, 2023 | -7.98 Mn |
| Mar 31, 2023 | -9.67 Mn |
| Dec 31, 2022 | -8.52 Mn |
| Sep 30, 2022 | -8.26 Mn |
| Jun 30, 2022 | -9.23 Mn |
| Mar 31, 2022 | -9.09 Mn |
| Dec 31, 2021 | -11.05 Mn |
| Sep 30, 2021 | -22.30 Mn |
| Jun 30, 2021 | -22.64 Mn |